Comparison effect of migroherb herbal drug( Tanacetum parthenium, Matricaria chamomilla and magnesium) and Venlafaxine in migraine

Phase 3

Recruiting

• Conditions: Migraine; migraine.

• Registration Number: IRCT20231009059670N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Ages 18-65 years
Confirmation of episodic migraine by a neurologist according to the latest ICHD definition

Exclusion Criteria

Use of corticosteroids
Use of vitamin D, calcium and riboflavin supplements
Using other anti-migraine drugs (including beta-blockers, anti-seizures, calcium blockers, tricyclic antidepressants, nerve block or stimulation) except sodium valproate 200 mg daily
Presence of tension headache
Diagnosis of chronic migraine
Having a history of liver, kidney and hyper parathyroid diseases
Pregnancy and breastfeeding
People with trigeminal autonomic cephalalgia and neuralgia
People with secondary headaches
Patients using OCP and undergoing HRT treatment
Migraine headache onset age after 50 years
Excessive consumption of alcohol and drugs
Known cases of psychosis, major depression, bipolar disorder

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Impact on quality of life. Timepoint: At the beginning of the study (before the start of the intervention) and one month, two months and three months after the start of Migroherb or Venlafaxine. Method of measurement: HIT6 (Headache Impact Test) questionnaire.;Headache attacks frequency. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.;Severity of headache attacks. Timepoint: At the beginning of the study (before the start of the intervention) and three months after the start of migroherb or venlafaxine. Method of measurement: MIDAS (Migraine Disability Assessment) questioner.